Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Operations: 2010-2024

Historic Cash from Operations for Kura Oncology (KURA) over the last 14 years, with Dec 2024 value amounting to $134.3 million.

  • Kura Oncology's Cash from Operations fell 85.61% to -$80.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year change of. This contributed to the annual value of $134.3 million for FY2024, which is 207.61% up from last year.
  • Latest data reveals that Kura Oncology reported Cash from Operations of $134.3 million as of FY2024, which was up 207.61% from -$124.8 million recorded in FY2023.
  • Over the past 5 years, Kura Oncology's Cash from Operations peaked at $134.3 million during FY2024, and registered a low of -$124.8 million during FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$110.1 million (2022), whereas its average is -$33.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 49.72% in 2021, then soared by 207.61% in 2024.
  • Over the past 5 years, Kura Oncology's Cash from Operations (Yearly) stood at -$69.8 million in 2020, then plummeted by 49.72% to -$104.6 million in 2021, then declined by 5.27% to -$110.1 million in 2022, then fell by 13.41% to -$124.8 million in 2023, then soared by 207.61% to $134.3 million in 2024.